Top Markets
Coin of the day
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Classement en actions #25519
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Prix de l'action
$9.81
Dernière synchronisation: 2025-03-18
Capitalisation boursière
$48.68M
Changement (1 jour)
1.55%
Changement (1 an)
0.00%
Pays
US
Échange AlloVir, Inc. (ALVR)

Catégorie

Ratio P/S pour AlloVir, Inc. (ALVR)
Ratio P/S au August 2026 TTM : 0.00
Selon les derniers rapports financiers et le cours de l'action de AlloVir, Inc., le ratio cours/ventes actuel (TTM) est 0.00. À la fin de 2023, le ratio P/S était de 0.00.
Historique du ratio P/S pour AlloVir, Inc. de 2022 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
11.28 -
US